Steven Cohen's RNA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 22,708 shares of Atrium Therapeutics, Inc. (RNA) worth $303,606, representing 0.00% of the portfolio. First purchased in 2021-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in RNA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2023, adding 60,584 shares. Largest reduction occurred in Q4 2021, reducing 201,000 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Atrium Therapeutics (RNA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Atrium Therapeutics (RNA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +22,708 | New Buy | 22,708 | $13.37 |
| Q4 2023 | -60,584 | Sold Out | 0 | $0.00 |
| Q3 2023 | +60,584 | New Buy | 60,584 | $6.38 |
| Q4 2021 | -201,000 | Sold Out | 0 | $0.00 |
| Q3 2021 | +201,000 | New Buy | 201,000 | $24.63 |
Steven Cohen's Atrium Therapeutics Investment FAQs
Steven Cohen first purchased Atrium Therapeutics, Inc. (RNA) in Q3 2021, acquiring 201,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Atrium Therapeutics, Inc. (RNA) for 5 quarters since Q3 2021.
Steven Cohen's largest addition to Atrium Therapeutics, Inc. (RNA) was in Q3 2021, adding 201,000 shares worth $4.95 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 22,708 shares of Atrium Therapeutics, Inc. (RNA), valued at approximately $303,606.
As of the Q1 2026 filing, Atrium Therapeutics, Inc. (RNA) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Atrium Therapeutics, Inc. (RNA) was 201,000 shares, as reported at the end of Q3 2021.